Specific causes of death among patients with cardiac sarcoma in the United States-An analysis of The Surveillance, Epidemiology, and End Results (SEER) Program.
SEER-database
cardiac neoplasms
cardiac sarcoma
Journal
Journal of cardiac surgery
ISSN: 1540-8191
Titre abrégé: J Card Surg
Pays: United States
ID NLM: 8908809
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
29
07
2022
accepted:
11
08
2022
pubmed:
19
8
2022
medline:
12
10
2022
entrez:
18
8
2022
Statut:
ppublish
Résumé
Representing 10%-25% of the primary cardiac neoplasms, primary malignant cardiac tumors (PMCT) have a poor prognosis, yet with rare incidence. Constituting more than 50% of the PMCT, cardiac sarcoma has increased not only in incidence over the past five decades but also in severity. Patients with PMCTs, especially sarcomas, have the worst prognosis when compared with other cardiac or extracardiac tumors. This retrospective study was performed using SEER*stat software, latest version 8.3.9.2(5) by accessing seer 18 registries plus data (excl AK) Nov 2020 Sub (2000-2018) for standard mortality ratio (SMR). A total of 235 patients were identified of whom 49.4% were females. Most of our patients were Stage 4 (n = 81) and distant in location (n = 92). The most common treatment method was tumor-directed surgery (n = 164), chemotherapy (n = 146), and radiotherapy (n = 55). Furthermore, other associated cancers with cardiac sarcoma were rare, with ten cases with lung and bronchus cancer (SMR: 37.95, 95% confidence interval [CI]: 18.2, 69.8), four with bone and joints (SMR: 1726.05, 95% CI: 470.2, 4419.3). During a 5-year follow-up, 235 patients died primarily due to cardiac sarcoma (n = 182, 77.4%), other cancers (n = 34, 14.4%), and other noncancerous causes (n = 19, 8%), while the noncancerous causes were attributed mainly to cardiovascular diseases (n = 4, 21%, SMR: 4.95, 95% CI: 1.35, 12.67), septicemia (n = 2, 10.5%, SMR: 41.23, 95% CI: 4.99, 148.95).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3961-3963Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Oliveira GH, Al-Kindi SG, Hoimes C, Park SJ. Characteristics and survival of malignant cardiac tumors a 40-year analysis of >500 patients. Circulation. 2015;132(25):2395-2402.
Habib RH, Zacharias A, Schwann TA, Riordan CJ, Durham SJ, Shah A. Sex differences in mortality after coronary artery bypass graft surgery [3] (multiple letters). J Am Med Assoc. 2004;292(1):40-41.
Wang JG. Primary cardiac tumors. Right Hear Pathol From Mech to Manag. 2018;3:489-514.
https://seer.cancer.gov/statfacts/html/soft.html.
SEER*Stat.Version 8.3.9.2 National Cancer Institute Surveillance, Epidemiology, and EndResultsProgram; 2018. https://www.seer.cancer.gov/seerstat
Stiller CA, Trama A, Serraino D, et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer. 2013;49(3):684-695.
K Z, M L. Resection for thoracic metastases from sarcoma. Oncology. 2011;25(12):1198-1204.
Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37-49.
Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “international registry of lung metastases”. J Thorac Oncol. 2011;6(8):1373-1378.
Sayed A, Abdelfattah OM, Munir M, et al. Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & Bayesian network meta-analysis. Eur J Cancer. 2022;169:82-92.
Shantakumar S, Olsen M, Vo TT, Nørgaard M, Pedersen L. Cardiac dysfunction among soft tissue sarcoma patients in Denmark. Clin Epidemiol. 2016;8:53-59.
https://www.cancer.gov/about-cancer/treatment/side-effects/infection.